Differential CSF biomarker levels in APOE-ε4-positive and -negative patients with memory impairment

Dementia and Geriatric Cognitive Disorders

Volumn 23, Issue 2, 2007, Pages 87-95

  Andersson, Christin ^a   Blennow, Kaj ^c   Johansson, Sven Erik ^a   Almkvist, Ove ^a,b   Engfeldt, Peter ^d   Lindau, Maria ^e   Eriksdotter Jönhagen, Maria ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d ÖREBRO UNIVERSITY   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Apolipoprotein E genotype; Cognitive decline; CSF biomarkers; Episodic memory

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; TAU PROTEIN;

ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORRELATION ANALYSIS; EPISODIC MEMORY; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM; STATISTICAL SIGNIFICANCE;

EID: 33846253970     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000097354     Document Type: Article

References (45)

1. Tierney M, Szalai JP, Snow WG, et al: Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology 1996;46:661-665.
2. Almkvist O, Basun H, Bäckman L, et al: Mild cognitive impairment - An early stage of Alzheimer's disease? J Neural Transm 1998;54(suppl):21-29.
3. Petersen R, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment. Arch Neurol 1999;56:303-308.
4. Arnàiz E, Almkvist O: Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease. Acta Neurol Scand 2003;179(suppl):34-41.
5. Andersson C, Lindau M, Almkvist O, Engfeldt P, Johansson SE, Eriksdotter-Jönhagen M: Identifying patients at high and low risk for cognitive decline using Rey Auditory Verbal Learning Test among middle-aged memory clinic out-patients. Dement Geriatr Cogn Disord 2006;21:251-259.
6. Tierney MC, Black SE, Szalai JP, et al: Recognition memory and verbal fluency differentiate probable Alzheimer's disease from subcortical ischemic vascular dementia. Arch Neurol 2001;58:1654-1659.
7. Traykov L, Baudic S, Thibaudet MC, Rigaud AS, Smagghe A, Boller F: Neuropsychological deficit in early subcortical dementia: comparison to Alzheimer's disease. Dement Geriatr Cogn Disord 2002;14:26-32.
8. Looi JC, Sachdev PS: Differentiation of vascular dementia from AD on neuropsychological tests. Neurology 1999;53:670-678.
9. Jones S, Jonsson Laukka E, Small BJ, Fratiglioni L, Bäckman L: A preclinical phase in vascular dementia: cognitive impairment three years before diagnosis. Dement Geriatr Cogn Disord 2004;18:233-239.
10. Laukka EJ, Jones S, Small BJ, Fratiglioni L, Bäckman L: Similar patterns of cognitive deficits in the preclinical phases of vascular dementia and Alzheimer's disease. J Int Neuropsychol Soc 2004;10:382-391.
11. Blennow K: CSF biomarkers for mild cognitive impairment. J Intern Med 2004;256:224-234.
12. Andreasen N, Minthon L, Davidsson P, et al: Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol 2001;58:373-379.
13. Sunderland T, Linker G, Mirza N, et al: Decreased β-amyloid 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003;289:2094-2103.
14. Galasko D, Chang L, Clark CM, et al: High cerebrospinal fluid tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 1998;55:937-945.
15. Hsiung GR, Sadovnick D, Feldman H: Apolipoprotein E ε4 genotype as a genetic risk factor for cognitive decline and dementia: data from the Canadian study of health and aging. CMAJ 2004;171:863-867.
16. Tsuang DW, Wilson RK, Lopez OL, et al: Genetic association between the APOE*4 allele and Lewy bodies in Alzheimer disease. Neurology 2005;64:509-513.
17. Lasser RA, Dukoff R, Levy J, et al: Apolipoprotein E ε4 allele in association with global cognitive performance and CSF markers and Alzheimer's disease. Int J Geriatr Psychiatry 1998;13:767-774.
18. Ganzer S, Arlt S, Schoder V, et al: CSF-tau, CSF-Aβ1-42, ApoE-genotype and clinical parameters in the diagnosis of Alzheimer's disease: combination of CSF-tau and MMSE yields highest sensitivity and specificity. J Neural Transm 2003;110:1149-1160.
19. Tapiola T, PirttiläT, Mehta P, Alafuzoff I, Lehtovirta M, Soininen H: Relationship between apoE genotype and CSF β-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol Aging 2000;21:735-740.
20. Golombowski S, Müller-Spahn F, Romig H, Mendla K, Hock C: Dependence of cerebrospinal fluid tau protein levels on apolipoprotein E4 allele frequency in patients with Alzheimer's disease. Neurosci Lett 1997;225:213-215.
21. Riemenschneider M, Schmolke M, Lautenschlager N, et al: Cerebrospinal beta-amyloid (1-42) in early Alzheimer's disease: association with apolipoprotein E genotype and cognitive decline. Neurosci Lett 2000;284:85-88.
22. Sunderland T, Mirza N, Putnam KT, et al: Cerebrospinal fluid β-amyloid 1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of ApoE ε4 allele. Biol Psychiatry 2004;56: 670-676.
23. Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K: APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42. Neurology 2004;62:2116-2118.
24. Ivaniou A, Sindic C: Cerebrospinal fluid tau protein and amyloid β42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination. Neurocase 2005;11:32-39.
25. Schoonenboom SNM, Visser PJ, Mulder C, et al: Biomarker profiles and their relation to clinical variables in mild cognitive impairment. Neurocase 2005;11:8-13.
26. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-944.
27. Blennow K, Vanmechelen E: CSF markers for pathogenic processes in Alzheimer's disease: diagnostic implications and use in clinical neurochemistry. Brain Res Bull 2003;61:235-242.
28. Visser PJ, Scheltens P, Verhey FRJ: Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? J Neurol Neurosurg Psychiatry 2005;76:1348-1354.
29. Schmidt M: Rey Auditory Verbal Learning Test - A Handbook. Los Angeles, Western Psychological Services, 1996.
30. Folstein M, Folstein S, McHugh P: Minimental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
31. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4 (DSM IV). Washington, American Psychiatric Association, 1994.
32. Bartfai A, Nyman H, Stegman B: Wechsler adult intelligence scale revised. WAIS-R Manual. Stockholm, Psykologiförlaget, 1994.
33. Andersson E, Berg S, Lawenius M, Svanborg A: Intellectual functioning in a 70-year-old urban population. Acta Psychiatr Scand 1978;57:59-66.
34. Reitan R, Wolfson D: The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Tucson, Neuropsychology Press, 1993.
35. Fernaeus SE, Almkvist O: Word production: dissociation of two retrieval modes of semantic memory across time. J Clin Exp Neuropsychol 1998;20:137-143.
36. Lezak M: Neuropsychological Assessment, ed 3. New York, Oxford University Press, 1995.
37. Wechsler D: Wechsler Memory Scale - Revised. New York, Psychological Corporation, 1987.
38. Blennow K, Wallin A, Ågren H, Spenger C, Siegfried J, Vanmechelen E: Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer's disease? Mol Chem Neuropathol 1995;26:231-245.
39. Vanmechelen E, Vanderstichele H, Davidsson P, et al: Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 2000;285:49-52.
40. Andreasen N, Hesse C, Davidsson P, et al: Cerebrospinal fluid C-amyloid(1-42) in Alzheimer's disease: differences between early- and late-onset AD and stability during the course of disease. Arch Neurol 1999;56:673-680.
41. Hixson JE, Vernier DT: Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhAI. J Lipid Res 1990;31:545-548.
42. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239-259.
43. Guillozet A, Weintraub S, Mash D, Mesulam M: Neurofibrillary tangles, amyloid and memory in aging and mild cognitive impairment. Arch Neurol 2003;60:729-736.
44. Traykov L, Baudic S, Raoux N, et al: Patterns of memory impairment and perseverative behavior discriminate early Alzheimer's disease from subcortical vascular dementia. J Neurol Sci 2005;229-230:75-79.
45. Wahlund LO, Pihlstrand E, Eriksdotter-Jönhagen M: Mild cognitive impairment: experience from a memory clinic. Acta Neurol Scand 2003;107(suppl 179):21-24.